康艾注射液联合DP方案治疗晚期非小细胞肺癌对照研究

目的观察康艾注射液联合多西他赛和顺铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效和不良反应。方法70例晚期NSCLC患者分为联合康艾注射液化疗组（40例）和单化疗组（30例），观察2组患者化疗2个疗程后有效率（RR）及临床获益率（cB）、化疗期间及化疗后2组患者毒副作用观察及生存质量的改善情况。结果联合康艾注射液化疗组有效率及临床获益率均略高于单化疗组，差异有统计学意义（P〈0．05）。康艾＋化疗组化疗毒副反应在胃肠道反应、骨髓抑制、脱发及疲劳方面均低于单化疗组，差异有统计学意义（P〈0．05）。康艾＋化疗组生存质量改善，卡氏评分（KPS评分）提高，改善率达到62．50％，2组比较差异有统计学意义（P〈0．05）。结论康艾注射液能提高多西他赛＋顺铂的近期疗效，减轻化疗的毒副反应，提高生存质量。

Contrast of combined chemotherapy with Kangai injection plus DP regimen for advanced non-small cell lung cancer

Objective To evaluate the efficacy and acute toxicity of combined chemotherapy with Kangai injection, docetaxel and cisplatin regimen for the advanced non-small cell lung cancer （NSCLC）. Methods Seventy patients with NSCLC were divided into 2 groups： combined chemotherapy group （n=40） and conventional chemotherapy group （n =30）. The efficiencies including response rates and clinical benefit rates were evaluated after 2 cycles. The incidences of chemotherapy toxicity and life qualities of the two groups were observed. Results The response rate and clinical benefit rate in the combined chemotherapy group were both significantly higher than those in the conventional chemotherapy group （P〈0.05）. The incidences of chemotherapy toxicities of gastrointestinal, bone marrow, fatigue and hair losing in the combined chemotherapy group were significantly lower than those in the conventional chemotherapy group （P〈0.05）. The life quality of patients in the combined chemotherapy group improved to 62. 50% and karnofsky performance score （KPS） was significantly increased （P〈0.05）. Conclusion Kangai injection can enhance the shortterm treatment efficacy and decrease the incidence of the toxicities of docetaxel and cisplatin, leading to improvement of the life quality of patients with advanced NSCLC.